| Year |
Citation |
Score |
| 2024 |
Diep CH, Spartz A, Truong TH, Dwyer AR, El-Ashry D, Lange CA. Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer. Endocrinology. PMID 39041201 DOI: 10.1210/endocr/bqae092 |
0.622 |
|
| 2022 |
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, ... El-Ashry D, et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Research. PMID 35078818 DOI: 10.1158/0008-5472.CAN-21-2576 |
0.519 |
|
| 2021 |
Sharma U, Medina-Saenz K, Miller PC, Troness B, Spartz A, Sandoval-Leon A, Parke DN, Seagroves TN, Lippman ME, El-Ashry D. Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis. Breast Cancer Research and Treatment. PMID 34216317 DOI: 10.1007/s10549-021-06299-0 |
0.431 |
|
| 2020 |
Dey P, Wang A, Ziegler Y, Kim SH, El-Ashry D, Katzenellenbogen JA, Katzenellenbogen BS. Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer. Cancers. 12. PMID 32961773 DOI: 10.3390/Cancers12092677 |
0.651 |
|
| 2020 |
Katzenellenbogen BS, Ziegler Y, Laws MJ, Guillen VS, Kim S, Dey P, Smith BP, Gong P, Bindman N, Zhao Y, Carlson K, Yasuda MA, Singh D, Li Z, El-Ashry D, et al. Abstract P5-05-05: Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-05-05 |
0.524 |
|
| 2020 |
Troness BC, Spartz A, Sharma U, McCarthy J, El-Ashry D. Abstract 5117: CD44 and its ligand, hyaluronic acid, mediate co-clustering between breast cancer cells and cancer associated fibroblasts Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5117 |
0.537 |
|
| 2019 |
Miller PC, El-Ashry D, Lippman ME. Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer. Cancer Drug Resistance (Alhambra, Calif.). 2: 1215-1223. PMID 35582279 DOI: 10.20517/cdr.2019.99 |
0.562 |
|
| 2019 |
Ziegler Y, Laws MJ, Sanabria Guillen V, Kim SH, Dey P, Smith BP, Gong P, Bindman N, Zhao Y, Carlson K, Yasuda MA, Singh D, Li Z, El-Ashry D, Madak-Erdogan Z, et al. Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds. Npj Breast Cancer. 5: 45. PMID 31815181 DOI: 10.1038/s41523-019-0141-7 |
0.578 |
|
| 2019 |
Drews-Elger K, Sandoval-Leon AC, Ergonul AB, Jegg AM, Gomez-Fernandez C, Miller PC, El-Ashry D, Lippman ME. Paget's disease of the nipple in a Her2-positive breast cancer xenograft model. Breast Cancer Research and Treatment. PMID 31720992 DOI: 10.1007/S10549-019-05490-8 |
0.489 |
|
| 2018 |
McCarthy JB, El-Ashry D, Turley EA. Corrigendum: Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression. Frontiers in Cell and Developmental Biology. 6: 112. PMID 30310812 DOI: 10.3389/Fcell.2018.00112 |
0.45 |
|
| 2018 |
McCarthy JB, El-Ashry D, Turley EA. Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression. Frontiers in Cell and Developmental Biology. 6: 48. PMID 29868579 DOI: 10.3389/Fcell.2018.00048 |
0.404 |
|
| 2018 |
Agarwal A, Balic M, El-Ashry D, Cote RJ. Circulating Tumor Cells: Strategies for Capture, Analyses, and Propagation. Cancer Journal (Sudbury, Mass.). 24: 70-77. PMID 29601333 DOI: 10.1097/Ppo.0000000000000310 |
0.486 |
|
| 2018 |
Picon-Ruiz M, Pan C, Drewes-Elger K, Jang K, Besser A, Zaho D, Morata-Tarifa C, Kim M, Ince T, Azzam D, Wander S, Cote R, Guy H, El-Ashry D, Torne-Poyatos P, et al. Abstract P6-05-01: Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/SOX2/miR-302b mediated malignant progression Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-05-01 |
0.497 |
|
| 2017 |
Miller P, Kidwell KM, Thomas D, Sabel M, Rae JM, Hayes DF, Hudson BI, El-Ashry D, Lippman ME. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome. Breast Cancer Research and Treatment. PMID 28717852 DOI: 10.1007/S10549-017-4366-6 |
0.664 |
|
| 2017 |
Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X, Merchan JR. Molecular Effects of Stromal Selective Targeting by uPAR Retargeted Oncolytic Virus in Breast Cancer. Molecular Cancer Research : McR. PMID 28679779 DOI: 10.1158/1541-7786.Mcr-17-0016 |
0.521 |
|
| 2017 |
Kim M, Jang K, Miller P, Picon-Ruiz M, Yeasky TM, El-Ashry D, Slingerland JM. VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. Oncogene. PMID 28504716 DOI: 10.1038/Onc.2017.4 |
0.43 |
|
| 2017 |
Bishopric N, Speransky S, Serafini P, Fuente ADl, Bicciato S, El-Ashry D, Lippman M. Abstract P6-01-05: Novel cytotoxic RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-01-05 |
0.479 |
|
| 2017 |
Kwak T, Drews-Elger K, Ergonul A, Braley A, Hwang G, El-Ashry D, Slingerland J, Lippman M, Hudson B. Abstract P3-06-01: Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-06-01 |
0.489 |
|
| 2017 |
Sharma U, Miller P, Medina-Saenz K, Ferrer P, Speransky S, Yeasky T, El-Ashry D. Abstract 5895: Circulating CAF and cCAF circulating tumor cell co clusters are associated with metastatic breast cancer Cancer Research. 77: 5895-5895. DOI: 10.1158/1538-7445.Am2017-5895 |
0.595 |
|
| 2016 |
Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. PMID 27669433 DOI: 10.1038/Onc.2016.324 |
0.586 |
|
| 2016 |
Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, ... ... El-Ashry D, et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Research. PMID 26744520 DOI: 10.1158/0008-5472.Can-15-0927 |
0.607 |
|
| 2016 |
Slingerland J, Picon-Ruiz M, Jang K, Morata-Tarifa C, Pan C, Besser A, Kim M, Ince T, Howard G, El-Ashry D. Abstract P1-03-02: Estrogens contribute to cytokine upregulation and cancer stem cell recruitment upon breast cancer contact with mature human mammary adipocytes: Effects of estrogen type and adipocyte donor weight Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-03-02 |
0.645 |
|
| 2016 |
Shah SH, Miller P, Machlin L, Medina-Saenz K, Parajuli R, Lippman ME, El-Ashry D. Abstract 4396: Circulating CAFs and CAF-secreted factors may be indicative of breast cancer metastasis Cancer Research. 76: 4396-4396. DOI: 10.1158/1538-7445.Am2016-4396 |
0.678 |
|
| 2015 |
Hew K, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford PA, Guo W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482043 DOI: 10.1158/1078-0432.Ccr-15-0534 |
0.478 |
|
| 2015 |
Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, Williams AJ, Cote RJ, Lippman ME, Datar RH, El-Ashry D. Identification of cancer associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Research. PMID 26471358 DOI: 10.1158/0008-5472.Can-15-1633 |
0.609 |
|
| 2015 |
Shah SH, Miller P, Garcia-Contreras M, Ao Z, Machlin L, Issa E, El-Ashry D. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype. Cancer Biology & Therapy. 1-11. PMID 26186233 DOI: 10.1080/15384047.2015.1071742 |
0.671 |
|
| 2015 |
Miller PC, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 373-85. PMID 25370469 DOI: 10.1158/1078-0432.Ccr-14-2053 |
0.574 |
|
| 2015 |
Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34: 3107-19. PMID 25151964 DOI: 10.1038/Onc.2014.257 |
0.492 |
|
| 2015 |
Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F. Abstract AS31: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-As31 |
0.542 |
|
| 2015 |
Miller P, Clarke J, El-Ashry D. Abstract P4-07-07: A MAPK microRNA signature significantly associated with poor outcome and predictive of response to tamoxifen therapy in ER+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-07-07 |
0.601 |
|
| 2015 |
Shah SH, Miller P, Ao Z, Issa E, Elger KD, Datar R, Lippman M, El-Ashry D. Abstract P4-04-15: Hierarchy of breast cancer associated fibroblasts communicate with cancer cells via microRNAs to drive breast cancer progression Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-04-15 |
0.677 |
|
| 2015 |
Shah SH, Miller P, Issa E, Drews-Elger K, El-Ashry D. Abstract B39: Stromal miRNAs as mediators of mitogen activated protein kinase-induced estrogen repression in breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B39 |
0.613 |
|
| 2015 |
Shah S, Ao Z, Miller P, Dattar R, Lippman M, El-Ashry D. Abstract 4027: Aggressive breast cancer associated fibroblasts communicate with cancer cells via microRNAs and promote an aggressive breast cancer phenotype Cancer Research. 75: 4027-4027. DOI: 10.1158/1538-7445.Am2015-4027 |
0.631 |
|
| 2015 |
Hew K, Miller P, El-Ashry D, Wei Z, Sun J, Zhang G, Guo W, Brafford P, Mills G, Slingerland J, Simpkins F. The effects of combined MEK inhibition and antiestrogen therapy in the treatment of ovarian cancer Gynecologic Oncology. 137: 182. DOI: 10.1016/J.Ygyno.2015.01.457 |
0.385 |
|
| 2014 |
Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, El-Ashry D, Hematti P, Polyak K, Mechta-Grigoriou F, Mariani O, et al. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 15: 762-74. PMID 25515522 DOI: 10.1016/J.Stem.2014.10.001 |
0.644 |
|
| 2014 |
Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, Clarke J, Campion-Flora A, Rodrigues DN, Reis-Filho JS, Rae JM, Thomas D, Berry D, El-Ashry D, Lippman ME. Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome. Breast Cancer Research and Treatment. 148: 41-59. PMID 25270120 DOI: 10.1007/S10549-014-3122-4 |
0.552 |
|
| 2014 |
Plotkin A, Volmar CH, Wahlestedt C, Ayad N, El-Ashry D. Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. Breast Cancer Research and Treatment. 147: 249-63. PMID 25129342 DOI: 10.1007/S10549-014-3093-5 |
0.594 |
|
| 2014 |
Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 144: 503-17. PMID 24567196 DOI: 10.1007/S10549-014-2887-9 |
0.586 |
|
| 2014 |
Madak-Erdogan Z, El-Ashry D, Katzenellenbogen BS. Abstract 4169: ERK2 functional chromatin footprints in patient-derived breast tumor cells predict molecular subtype, clinical outcome, and drug response in breast cancers Cancer Research. 74: 4169-4169. DOI: 10.1158/1538-7445.Am2014-4169 |
0.624 |
|
| 2014 |
Plotkin AJ, Volmar C, Ayad N, El-Ashry D. Abstract 2098: Histone deacetylation underlying hMAPK-induced ER mRNA repression Cancer Research. 74: 2098-2098. DOI: 10.1158/1538-7445.Am2014-2098 |
0.619 |
|
| 2013 |
Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. Embo Molecular Medicine. 5: 1502-22. PMID 23982961 DOI: 10.1002/Emmm.201302558 |
0.401 |
|
| 2013 |
Shah SH, Miller P, Drews-Elger K, Brinkman J, Lairet S, Steinberg A, El-Ashry D. Abstract B108: Cancer-associated fibroblasts contribute to establishment of ER-negative breast cancer phenotype through secreted factors and miRNAs Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B108 |
0.697 |
|
| 2013 |
Miller PC, Shah S, Lairet S, Steinberg A, Heyn A, Benito D, El-Ashry D. Abstract 5325: Co-culture induced EMT in breast tumor cells is mediated through MAPK signaling and microRNA regulation. Cancer Research. 73: 5325-5325. DOI: 10.1158/1538-7445.Am2013-5325 |
0.483 |
|
| 2013 |
Miller P, Lairet S, El-Ashry D. Abstract P4-07-01: Upregulation of miR-224 in breast cancer exhibiting hyperactivation of ERK1/2 MAPK signaling associates with repression of Raf kinase inhibitory protein and poor clinical outcome Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-07-01 |
0.587 |
|
| 2012 |
Philip MC, Lairet S, Clarke J, Richer J, El-Ashry D. Abstract 3171: Hyperactive MAPK dysregulation of microRNAs contributes to the ER-negative phenotype in breast cancer Cancer Research. 72: 3171-3171. DOI: 10.1158/1538-7445.Am2012-3171 |
0.673 |
|
| 2012 |
Miller P, El-Ashry D. Abstract P5-10-08: Hyperactive MAPK signaling alters expression of miR-221/222 and miR-30 families, which impacts multiple pathways and contributes to breast cancer aggressiveness and progression Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-10-08 |
0.53 |
|
| 2012 |
Drews-Elger K, Iorns E, Brinkman J, Berry D, Lippman M, El-Ashry D. Abstract P1-05-12: Metastatic xenograft models of human estrogen receptor negative breast cancer primary cultures are driven by the recruitment of myeloid-derived suppressor cells Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P1-05-12 |
0.653 |
|
| 2011 |
Bayraktar UD, Kim TK, Drews-Elger K, Benjamin C, El-Ashry D, Wieder E, Komanduri KV. Simultaneous measurement of ERα, HER2, and phosphoERK1/2 in breast cancer cell lines by flow cytometry. Breast Cancer Research and Treatment. 129: 623-8. PMID 21607585 DOI: 10.1007/S10549-011-1586-Z |
0.613 |
|
| 2011 |
Miller PC, Clarke J, Koru-Sengal T, Brinkman J, El-Ashry D. Abstract 3946: Investigation of a hyperactive MAPK microRNA expression profile reveals potential role for microRNAs in the generation and maintenance of ER- phenotype in breast cancer Cancer Research. 71: 3946-3946. DOI: 10.1158/1538-7445.Am2011-3946 |
0.557 |
|
| 2011 |
Azzam DJ, Drews-Elger K, Zhao D, Chendong P, Wander SA, El-Ashry D, Slingerland JM. Abstract 3335: Self-renewal, tumorigenicity and metastatic potential of CD44+ cells in ER-negative lines and dissociated primary human breast cancers is increased in CD24+ subsets Cancer Research. 71: 3335-3335. DOI: 10.1158/1538-7445.Am2011-3335 |
0.423 |
|
| 2011 |
Drews-Elger K, Brinkman JA, Azzam DJ, Schlater A, Diehl KM, El-Ashry D. Abstract 2392: Primary cultures established from estrogen receptor negative breast tumors: Method and characterization Cancer Research. 71: 2392-2392. DOI: 10.1158/1538-7445.Am2011-2392 |
0.607 |
|
| 2011 |
Miller P, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D. P3-03-07: A Novel Approach Integrating microRNA and mRNA Signatures of HMAPK Signaling Is Highly Predictive of ER- Status and Outcome in Breast Cancer – Role of HMAPK microRNAs in Repression of ER and p27. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-03-07 |
0.559 |
|
| 2011 |
Drews-Elger K, Brinkman J, Dean S, El-Ashry D. P2-01-22: Characterization of Four ER-Negative Breast Primary Tumor Dissociated Cultures as a Model for the In Vitro and In Vivo Study of Tumorigenesis, Metastasis and Angiogenesis. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-01-22 |
0.619 |
|
| 2010 |
Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. Bmc Cancer. 10: 604. PMID 21050467 DOI: 10.1186/1471-2407-10-604 |
0.549 |
|
| 2010 |
Hnatyszyn HJ, Liu M, Hilger A, Herbert L, Gomez-Fernandez CR, Jorda M, Thomas D, Rae JM, El-Ashry D, Lippman ME. Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody. Breast Cancer Research and Treatment. 122: 371-80. PMID 19842031 DOI: 10.1007/S10549-009-0584-X |
0.609 |
|
| 2010 |
Miller P, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D. Abstract 4597: MAPK-mediated gene expression in ER-negative breast cancer: Role of miRNAs and Ago2 Cancer Research. 70: 4597-4597. DOI: 10.1158/1538-7445.Am10-4597 |
0.43 |
|
| 2009 |
Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. Journal of Mammary Gland Biology and Neoplasia. 14: 67-78. PMID 19263197 DOI: 10.1007/S10911-009-9113-0 |
0.651 |
|
| 2009 |
El-Ashry D, Brinkman J, Miller P. Identification of ER Negative Tumors in Which MAPK Inhibition Restores Both ER Expression and Anti-Estrogen Responses. Cancer Research. 69: 404-404. DOI: 10.1158/0008-5472.Sabcs-09-404 |
0.637 |
|
| 2009 |
Hnatyszyn H, Liu M, Gomez-Fernandez C, Jorda M, Rae J, El-Ashry D, Lippman M. Correlations between GREB1 Expression and Estrogen Receptor, HER2 Status in Human Breast Cancer. Cancer Research. 69: 2008-2008. DOI: 10.1158/0008-5472.Sabcs-09-2008 |
0.64 |
|
| 2007 |
Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7029-36. PMID 18056179 DOI: 10.1158/1078-0432.Ccr-07-0587 |
0.684 |
|
| 2006 |
Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Research. 66: 3903-11. PMID 16585219 DOI: 10.1158/0008-5472.Can-05-4363 |
0.676 |
|
| 2004 |
Marshall JL, Eisenberg SG, Johnson MD, Hanfelt J, Dorr FA, El-Ashry D, Oberst M, Fuxman Y, Holmlund J, Malik S. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 4: 268-74. PMID 15555210 DOI: 10.3816/Ccc.2004.N.026 |
0.357 |
|
| 2004 |
Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends in Endocrinology and Metabolism: Tem. 15: 193-7. PMID 15223047 DOI: 10.1016/J.Tem.2004.05.011 |
0.599 |
|
| 2004 |
Holloway JN, Murthy S, El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. Molecular Endocrinology (Baltimore, Md.). 18: 1396-410. PMID 15056731 DOI: 10.1210/Me.2004-0048 |
0.561 |
|
| 2004 |
Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biology & Therapy. 3: 460-7. PMID 15020841 DOI: 10.4161/Cbt.3.5.810 |
0.742 |
|
| 1999 |
Clarke R, Skaar T, El-Ashry D, Leonessa F, Hilakivi-Clarke LA. Use of ERE and reporter gene constructs to assess putative estrogenic activity. Journal of Medicinal Food. 2: 143-149. PMID 19281366 DOI: 10.1089/Jmf.1999.2.143 |
0.348 |
|
| 1999 |
Nass SJ, Ferguson AT, El-Ashry D, Nelson WG, Davidson NE. Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells Oncogene. 18: 7453-7461. PMID 10602504 DOI: 10.1038/Sj.Onc.1203138 |
0.547 |
|
| 1997 |
El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene. 15: 423-35. PMID 9242379 DOI: 10.1038/Sj.Onc.1201198 |
0.598 |
|
| 1996 |
El-Ashry D, Chrysogelos SA, Lippman ME, Kern FG. Estrogen induction of TGF-alpha is mediated by an estrogen response element composed of two imperfect palindromes. The Journal of Steroid Biochemistry and Molecular Biology. 59: 261-9. PMID 9010318 DOI: 10.1016/S0960-0760(96)00118-5 |
0.452 |
|
| 1996 |
Yarden RI, Lauber AH, El-Ashry D, Chrysogelos SA. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology. 137: 2739-2747. PMID 8770893 DOI: 10.1210/Endo.137.7.8770893 |
0.494 |
|
| 1995 |
Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Research and Treatment. 34: 97-117. PMID 7647336 DOI: 10.1007/Bf00665783 |
0.579 |
|
| 1994 |
El-Ashry D, Lippman ME. Molecular biology of breast carcinoma. World Journal of Surgery. 18: 12-20. PMID 8197767 DOI: 10.1007/Bf00348187 |
0.584 |
|
| 1993 |
Dickson RB, Johnson MD, el-Ashry D, Shi YE, Bano M, Zugmaier G, Ziff B, Lippman ME, Chrysogelos S. Breast cancer: influence of endocrine hormones, growth factors and genetic alterations. Advances in Experimental Medicine and Biology. 330: 119-41. PMID 8368129 DOI: 10.1007/978-1-4615-2926-2_10 |
0.601 |
|
| 1989 |
El-Ashry D, Onate SA, Nordeen SK, Edwards DP. Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form Molecular Endocrinology. 3: 1545-1558. PMID 2608048 DOI: 10.1210/Mend-3-10-1545 |
0.304 |
|
| Show low-probability matches. |